Blockade of TGF-β has been found to promote the anti-tumor activity of CD8+ T cells, thereby reversing the resistance to a PD-1/PD-L1 blockade in the TME (Chen et al., 2018). The gene discussed is TGFB1; the disease is neoplasm.